Literature DB >> 15284121

Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells.

Andrew M Hall1, Mark A Vickers, Ewan McLeod, Robert N Barker.   

Abstract

Chronic lymphocytic leukemia (CLL) is frequently associated with autoimmune diseases directed against constituents of the blood, including hemolytic anemia (AIHA). We hypothesized that CLL cells predispose to hematologic autoimmunity by acting as aberrant antigen-presenting cells (APCs). Initially, it was confirmed that all studied patients with AIHA secondary to CLL harbored activated helper T (T(H)) cells specific for epitopes on the dominant red blood cell (RBC) autoantigens in primary AIHA, the Rh proteins. Rh-specific T(H) cells were also detected in a number of patients with CLL who, although they did not have AIHA, had low levels of anti-RBC antibody in their sera. Fractionation of putative APC populations from the peripheral blood of patients by negative selection showed that CD5+ CLL cells are the most effective cell type in processing and presenting purified Rh protein to autoreactive T(H) cells. This ability was confirmed using positively selected CD5+ CLL cells. Thus, our study provides the first evidence for malignant cells driving an autoimmune response by acting as aberrant APCs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15284121     DOI: 10.1182/blood-2003-10-3563

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Healthy individuals have Goodpasture autoantigen-reactive T cells.

Authors:  Juan Zou; Sigrid Hannier; Lindsay S Cairns; Robert N Barker; Andrew J Rees; A Neil Turner; Richard G Phelps
Journal:  J Am Soc Nephrol       Date:  2008-01-23       Impact factor: 10.121

Review 2.  A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia.

Authors:  Mazie Tsang; Sameer A Parikh
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

Review 3.  Autoimmune complications in chronic lymphocytic leukaemia (CLL).

Authors:  Clive S Zent; Neil E Kay
Journal:  Best Pract Res Clin Haematol       Date:  2010-03       Impact factor: 3.020

4.  Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia.

Authors:  S Schliffke; N Akyüz; C T Ford; T Mährle; T Thenhausen; A Krohn-Grimberghe; S Knop; C Bokemeyer; M Binder
Journal:  Leukemia       Date:  2016-05-25       Impact factor: 11.528

5.  Anti-globulin test positivity indicates advanced disease in Indian CLL patients.

Authors:  Richa Gupta; Neha Garg; Abha Singh
Journal:  Am J Blood Res       Date:  2021-04-15

6.  Clinical and serological autoimmune complications in chronic lymphocytic leukemia.

Authors:  Cengiz Demir; Ömer Ekinci
Journal:  Wien Klin Wochenschr       Date:  2017-05-05       Impact factor: 1.704

7.  Atypical chronic lymphocytic leukemia with polyglandular autoimmune endocrinopathy type II: a complex profile.

Authors:  Preetesh Jain; Luis Baez-Vallecillo; Yang O Huh; Ohad Benjamini; Lynne Abruzzo; Susan O'Brien; Naveen Pemmaraju; Michael Keating; Robert F Gagel; Zeev Estrov
Journal:  Leuk Lymphoma       Date:  2014-01-24

8.  Production of the effector cytokine interleukin-17, rather than interferon-γ, is more strongly associated with autoimmune hemolytic anemia.

Authors:  Andrew M Hall; Omar M Zamzami; Natasha Whibley; Daniel P Hampsey; Anne M Haggart; Mark A Vickers; Robert N Barker
Journal:  Haematologica       Date:  2012-03-14       Impact factor: 9.941

9.  Myelin protein zero is naturally processed in the B cells of monoclonal gammopathy of undetermined significance of immunoglobulin M isotype: aberrant triggering of a patient's T cells.

Authors:  Eva Hellqvist; Maria Kvarnström; Anita Söderberg; Magnus Vrethem; Jan Ernerudh; Anders Rosén
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

Review 10.  Autoimmunity and lymphomagenesis.

Authors:  Lynn R Goldin; Ola Landgren
Journal:  Int J Cancer       Date:  2009-04-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.